Barclays PLC Decreases Stake in AtriCure, Inc. (NASDAQ:ATRC)

Barclays PLC lessened its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 57.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,265 shares of the medical device company’s stock after selling 174,803 shares during the quarter. Barclays PLC’s holdings in AtriCure were worth $3,625,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd purchased a new position in shares of AtriCure in the third quarter valued at $614,000. Wellington Management Group LLP grew its stake in shares of AtriCure by 0.4% in the 3rd quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company’s stock worth $43,291,000 after buying an additional 6,045 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of AtriCure by 14.6% in the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock worth $18,621,000 after buying an additional 84,700 shares during the last quarter. State Street Corp raised its position in shares of AtriCure by 4.9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock valued at $37,710,000 after buying an additional 63,002 shares in the last quarter. Finally, Arizona PSPRS Trust bought a new position in shares of AtriCure in the 3rd quarter valued at about $1,657,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Up 2.2 %

Shares of ATRC opened at $30.72 on Monday. The firm has a fifty day moving average price of $33.29 and a 200-day moving average price of $27.54. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.50 billion, a P/E ratio of -37.01 and a beta of 1.40. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $39.04.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The company had revenue of $115.91 million during the quarter, compared to analysts’ expectations of $112.23 million. During the same period in the previous year, the company earned ($0.20) EPS. The firm’s quarterly revenue was up 17.9% on a year-over-year basis. Equities research analysts expect that AtriCure, Inc. will post -0.72 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Canaccord Genuity Group boosted their price objective on AtriCure from $53.00 to $61.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. restated an “overweight” rating and set a $40.00 price target on shares of AtriCure in a report on Tuesday, December 17th. Needham & Company LLC lifted their price objective on shares of AtriCure from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. StockNews.com upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Saturday, September 14th. Finally, Oppenheimer raised their target price on shares of AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $42.00.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.